Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 6, 2011, Pages

  Dumitru, Alina F ^a   Shamji, Mohamed ^a   Wagenmann, Martin ^b   Hindersin, Simone ^b   Scheckenbach, Kathrin ^b   Greve, Jens ^c   Klenzner, Thomas ^b   Hess, Lorenzo ^d   Nebel, Sabine ^e   Zimmermann, Christian ^e   Zahner, Catherine ^e   Schmidt Weber, Carsten B ^a,f   Chaker, Adam M ^a,b,g  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Brunner and Hess Software AG   (Switzerland)

^e Zeller Medical AG   (Switzerland)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

allergic rhinitis; desloratadine; histamine; IL 8; nasal allergen challenge; nasal obstruction; Petasites hybridus; petasol butenoate complex; Randomized controlled trial; rhinomanometry; Ze 339

Indexed keywords

ANTIHISTAMINIC AGENT; DESLORATADINE; GRASS POLLEN EXTRACT; INTERLEUKIN 8; LEUKOTRIENE B4; PETASOL BUTENOATE; PLACEBO; UNCLASSIFIED DRUG; ZE 339;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSGEUSIA; EPISTAXIS; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HUMAN; INFLAMMATION; MALE; MORNING DOSAGE; NAUSEA; NOSE AIRFLOW; NOSE OBSTRUCTION; NOSE PROVOCATION TEST; NOSE SECRETION; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOMANOMETRY; SIDE EFFECT; SNEEZING; URTICARIA;

EID: 79957806285     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.02.045     Document Type: Article

References (26)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(suppl):S147-334.
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(suppl 86):8-160.
3. Nathan RA. The pathophysiology, clinical impact, and management of nasal congestion in allergic rhinitis. Clin Ther 2008;30:573-86. (Pubitemid 351680497)
4. Meltzer EO, Nathan R, Derebery J, Stang PE, Campbell UB, Yeh WS, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 2009;30:244-54.
5. Ciprandi G, Cirillo I, Klersy C, Marseglia GL, Caimmi D, Vizzaccaro A. Nasal obstruction is the key symptom in hayfever patients. Otolaryngol Head Neck Surg 2005;133:429-35. (Pubitemid 41247738)
6. Corey JP, Houser SM, Ng BA. Nasal congestion: a review of its etiology, evaluation, and treatment. Ear Nose Throat J 2000;79:690-3, 696, 698.
7. Patou J, De Smedt H, van Cauwenberge P, Bachert C. Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine. Clin Exp Allergy 2006;36:972-81. (Pubitemid 44166616)
8. McCain RW, Holden EP, Blackwell TR, Christman JW. Leukotriene B4 stimulates human polymorphonuclear leukocytes to synthesize and release interleukin-8 in vitro. Am J Respir Cell Mol Biol 1994;10:651-7.
9. Holmberg K, Tonnel AB, Dreyfus I, Olsson P, Cougnard J, Mesbah K, et al. Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009;64:1663-70.
10. Meltzer EO, Nathan RA, Derebery J, Dalal AA, Stanford RH, Corrao MA, et al. Physician perceptions of the treatment and management of allergic and nonallergic rhinitis. Allergy Asthma Proc 2009;30:75-83.
11. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116:338-44. (Pubitemid 38230294)
12. Thomet OA, Wiesmann UN, Blaser K, Simon HU. Differential inhibition of inflammatory effector functions by petasin, isopetasin and neopetasin in human eosinophils. Clin Exp Allergy 2001;31:1310-20. (Pubitemid 34208972)
13. Thomet OA, Wiesmann UN, Schapowal A, Bizer C, Simon HU. Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus. Biochem Pharmacol 2001;61:1041-7. (Pubitemid 32247393)
14. Schapowal A. Petasites Study Group. Butterbur Ze339 for the treatment of intermittent allergic rhinitis: dose-dependent efficacy in a prospective, randomized, double-blind, placebo-controlled study. Arch Otolaryngol Head Neck Surg 2004;130:1381-6. (Pubitemid 39603299)
15. Schapowal A. Study Group. Treating intermittent allergic rhinitis: a prospective, randomized, placebo and antihistamine-controlled study of Butterbur extract Ze 339. Phytother Res 2005;19:530-7. (Pubitemid 41345532)
16. Wagenmann M, Schumacher L, Bachert C. The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. Allergy 2005;60:1132-8. (Pubitemid 41153139)
17. Nathan RA, Eccles R, Howarth PH, Steinsvåg SK, Togias A. Objective monitoring of nasal patency and nasal physiology in rhinitis. J Allergy Clin Immunol 2005;115(suppl 1):S442-59.
18. Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Nasal obstruction in patients with seasonal allergic rhinitis: relationships between allergic inflammation and nasal airflow. Int Arch Allergy Immunol 2004;134:34-40. (Pubitemid 38698097)
19. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy 2004;34:958-64. (Pubitemid 38824076)
20. Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005;5:1800-8. (Pubitemid 41586220)
21. Weller CL, Collington SJ, Brown JK, Miller HR, Al-Kashi A, Clark P, et al. Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors. J Exp Med 2005;201:1961-71. (Pubitemid 41002932)
22. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006;118:773-88.
23. Mukaida N, Harada A, Matsushima K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev 1998;9:9-23. (Pubitemid 28280533)
24. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989;243:1464-6. (Pubitemid 19087128)
25. Douglass JA, Dhami D, Gurr CE, Bulpitt M, Shute JK, Howarth PH, et al. Influence of interleukin-8 challenge in the nasal mucosa in atopic and nonatopic subjects. Am J Respir Crit Care Med 1994;150:1108-13. (Pubitemid 24318043)
26. Brattström A, Schapowal A, Maillet I, Schnyder B, Ryffel B, Moser R. Petasites extract Ze 339 (PET) inhibits allergen-induced Th2 responses, airway inflammation and airway hyperreactivity in mice. Phytother Res 2010;24:680-5.